ASC30 vs HDG1901

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

ASC30

Developed by Ascletis Pharma

Phase 3 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07743450 (registry estimate)

No aligned efficacy figure on record for this race.

HDG1901

Developed by Hangzhou Zhongmei Huadong Pharmaceutical

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06739044 · Phase 3 · completed

This randomized, open-label Phase 3 trial compared HDG1901, a semaglutide biosimilar, with Ozempic in 490 adults with type 2 diabetes on metformin. The primary endpoint was the change in HbA1c at week 32, tested for equivalence with a margin of 0.4%. HbA1c fell by 2.047% with HDG1901 and 2.008% with Ozempic, a difference of -0.038% (95% CI -0.189 to 0.112). The whole confidence interval was inside the margin, so the trial showed equivalence. The figures come from the published ADA 2025 conference abstract.

Reported efficacy

Change in HbA1c from baseline (Week 32): HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met. (met)

Result source: NCT06739044

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointASC30HDG1901
HbA1c, change—Trial running · NCT07743450-2.0% vs -2.0%avs reference Ozempicwk 32NCT06739044
Body weight, change (kg)—Trial running · NCT07743450—Not posted · NCT06739044
HbA1c below 7%—Trial running · NCT07743450—Not posted · NCT06739044
Fasting plasma glucose, change—Trial running · NCT07743450—Not posted · NCT06739044
3-point MACE (% with event)—Trial running · NCT07743450—Not posted · NCT06739044

HbA1c, change

ASC30
—Trial running · NCT07743450
HDG1901
-2.0% vs -2.0%avs reference Ozempicwk 32NCT06739044

Body weight, change (kg)

ASC30
—Trial running · NCT07743450
HDG1901
—Not posted · NCT06739044

HbA1c below 7%

ASC30
—Trial running · NCT07743450
HDG1901
—Not posted · NCT06739044

Fasting plasma glucose, change

ASC30
—Trial running · NCT07743450
HDG1901
—Not posted · NCT06739044

3-point MACE (% with event)

ASC30
—Trial running · NCT07743450
HDG1901
—Not posted · NCT06739044
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ASC30: no structured comparison results are available for Type 2 Diabetes.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

HDG1901

HbA1c -2.047% vs -2.008% reference Ozempic @ 32wk
absolute change · percentage points
NCT06739044 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ASC30's landscape · HDG1901's landscape